RX Drugnews homepage



  • Visine L.R. Long Lasting Eye Drops (Pfizer Consumer)

    Description:    Visine L.R. is a sterile, isotonic, buffered ophthalmic solution containing the redness reliever oxymetazoline hydrochloride. Visine L.R. is specifically formulated to relieve redness of the eye in minutes with effective relief that lasts up to 6 hours.

    Active Ingredient:      Purpose:

    Oxymetazoline
        HCl 0.025% .......................... Redness reliever

    Use:

    • for the relief of redness of the eye due to minor eye irritations

    Warnings

    Ask a doctor before use if you have narrow angle glaucoma

    When using this product

    • overuse may cause more eye redness
    • remove contact lenses before using
    • do not use if this solution changes color or becomes cloudy
    • do not touch tip of container to any surface to avoid contamination
    • replace cap after each use

    Stop use and ask a doctor if

    • you feel eye pain
    • changes in vision occur
    • redness or irritation of the eye lasts
    • condition worsens or lasts more than 72 hours

    If pregnant or breast-feeding, ask a health professional before use.

    Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

    Directions:

    • adults and children 6 years of age and over: put 1 or 2 drops in the affected eye(s)
    • this may be repeated as needed every 6 hours or as directed by a doctor
    • children under 6 years of age: ask a doctor

    Other Information:

    • store at 15° to 25°C (59° to 77°F)

    Inactive Ingredients: benzalkonium chloride, boric acid, edetate disodium, purified water, sodium borate, and sodium chloride

    Questions? call 1-800-223-0182, weekdays 9 AM - 5 PM EST

    Caution:    Do not use if Visine imprinted neckband on bottle is broken or missing.

    How Supplied:    In ½ FL OZ and 1 FL OZ plastic dispenser bottle.


Subscribe to the "News" RSS Feed RSS

  ۞



 

About Us   |  Privacy Policy   |  Terms of Use   |  Contact Us  

© 2012 RxDrug News 1999-2016. All rights reserved